US 11286307
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11286307 (Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack) held by Takeda Pharmaceutical Company Limited expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/57